High Risk and Prevention

Transcription

1 Wednesday, April 28, 2010 Time Topic Presenter Aims 09:00-09:15 Welcome Dr. J.C. Acevedo & Kent C. Osborne, MD To give the welcome and explain some particularities of the actual meeting. High Risk and Prevention 09:15-09:45 Plenary Conference: Risk for breast cancer classification and its management in high risk women. 09:45-10:05 Breast imaging: Magnetic resonance, mammography and ultrasound for the surveillance in high risk population women. 10:05-10:25 Management of patients with high risk benign histology lesions. Dra. María Eugenia Bravo, Dr. Octavio Peralta Judy Garber, MD Director, Cancer Risk and Prevention Program; Associate Harvard Medical School, EE.UU. Emily Sedgwick, MD Assistant Professor of Radiology at Baylor Director of Breast Imaging at the Smith Breast Center, EE.UU. Octavio Peralta, MD Cirujano, Centro To discuss the methodology for different models of risk assessment and which of them could be used in a particular woman. To perform an up-date of the different methods utilized for the screening in high risk population. To discuss the management of patients with lesions that carry on increasing risk for breast cancer. Different medical and surgical procedures

2 10:25-10:45 Management of patients with breast cancer and BRCA 1 or 2 mutations, including contra-lateral breast. Judy Garber, MD Director, Cancer Risk and Prevention Program; Associate Harvard Medical School, EE.UU. for risk management. To discuss any special care for this type of patients (surgical, medical) and at the same time the type of care of the other breast (mainly imaging and surgical or medical prevention). 10:45-11:05 Coffee break All 11:05-11:25 Advances in breast cancer prevention. 11:25-11:45 Prevalence of pre-malignant and malignant lesions in specimens of women treated with prophylactic mastectomy. 11:45-12:05 Psychological counseling for high risk patient and her family. Judy Garber, MD Director, Cancer Risk and Prevention Program; Associate Harvard Medical School, EE.UU. Pablo Matamala, MD Anátomo Patólogo, Condes. Verónica Robert, Ps Psiconcóloga, Instituto Oncológico, Clínica Las Condes. To discuss the different strategies for breast cancer prevention. To review data about histological findings in specimens from prophylactic risk reduction mastectomies. To review the psychological impact of BRCA 1 and 2 testing and carrier for the woman and her family. Imaging of Breast Cancer 14:30-15:00 Plenary conference: Future of the breast imaging: MRI and spectroscopy, nano-technology, diffusion. Dra. Bernardita Aguirre, Dr. Álvaro Ibarra Emily Sedgwick, MD Assistant Professor of Radiology at Baylor Director of Breast Imaging at the Smith Breast Center, EE.UU. 15:00 15:20 Breast cancer screening: benefits Paulina Neira, MD Radióloga, Centro To give an analytic review of the data

3 and controversies. 15:20-15:40 Imaging the tumor in women undergoing neo-adjuvant therapy. Emily Sedgwick, MD Assistant Professor of Radiology at Baylor Director of Breast Imaging at the Smith Breast Center, EE.UU. regarding advances in breast cancer screening, utilizing different imaging methods. The use of imaging for the measurement of chemotherapy response in patients with neoadjuvant treatment is of crucial relevance. In this topic, the aim is to discuss the usefulness of different breast imaging methods and their results. 15:40-16:00 Coffee break All 16:00-16:20 BIRADS and pathological correlation for patients undergoing percutaneous biopsy. Dra. Bernardita Aguirre Radióloga, Centro Dr. Álvaro Ibarra Anátomo Patólogo, Condes To review the experience of the Breast Imaging Department from Clínica Las Condes and results from literature. 16:20-17:00 Clinical cases discussion Chairs: Dra. Bernardita Aguirre Radióloga, Centro In this section, clinical cases will be presented and discussed by the panel. Dr. Juan Carlos Acevedo Director Centro Integral de la Mama, Clínica Las Condes. Participants: Emily Sedgwick, MD Assistant Professor of Radiology at Baylor

4 Director of Breast Imaging at the Smith Breast Center, EE.UU. 17:00-17:30 Plenary Conference: The role of magnetic resonance imaging in the breast cancer patient. Fattaneh A. Tavassoli, MD Professor of Pathology and Obstetrics, Gynecology, and Reproductive Sciences; Director, Pathology Women's Health Program, Yale University School of Medicine, EE.UU. Monica Morrow, MD Chief of Breast Surgery at Memorial Sloan- Kettering Cancer Center in Manhattan, NY, EE.UU. Dr. Antonio Solá Radioncólogo Médico, Instituto Oncológico, Edith Perez, MD Professor of Medicine at Mayo Medical School, in Rochester, MN; Director of the Cancer Clinical Study Unit at the Mayo Clinic in Jacksonville, Florida, EE.UU. Dra. Bernardita Aguirre, Dra. Paulina Neira Monica Morrow, MD Chief of Breast Surgery at Memorial Sloan- Kettering Cancer Center in Manhattan, NY, EE.UU. To review the evidence that justify or not, the use of MRI in this patient setting.

5 17:30 19:30 Plenary Conference: The United States -Latin America Breast Cancer Pilot Project. Moderator: Dr. Juan Carlos Acevedo Jorge Gómez, MD Director, Office of Latin American Cancer Program Development. Office of the Director, National Cancer Institute, EE.UU. Dra. María Viniegra Oncóloga Clínica. Jefa del Servicio de Oncología de la Corporación Médica de San Martín, Buenos Aires, Argentina. Fernando Soares, MD, PhD Head, Dept. of Anatomic Pathology, Hospital A.C. Camargo, Sao Paulo, Brazil. To describe the methodology and objectives of this program, that is really important for Latin American countries. 19:30 Welcome reception Thursday, April 29, 2010 Pathology of Breast Cancer Time Topic Presenter Aims 09:00-09:30 Plenary Conference: Diagnostic and prognostic markers for breast cancer. Fattaneh A. Tavassoli, MD Professor of Pathology and Obstetrics, Gynecology, and Reproductive Sciences; Director, Pathology Women's Health Program, Yale University School of

6 09:30-09:50 Minimal residual disease and its significance for breast cancer therapy. 09:50-10:10 Micro and macro environment in breast cancer. Medicine, EE.UU. Luis Cereceda, MD Oncólogo Médico, Condes. Fattaneh A. Tavassoli, MD Professor of Pathology and Obstetrics, Gynecology, and Reproductive Sciences; Director, Pathology Women's Health Program, Yale University School of Medicine, EE.UU. To discuss the role of minimal residual disease both in lymph nodes and bone marrow and its importance for medical treatment decisions. 10:10-10:30 Tamoxifen and endometrium. Luis Contreras, MD Anátomo Patólogo, Condes. To describe the experience with. 10:30-11:00 Coffee break All 11:00-11:20 Ductal intra-epithelial neoplasm s: Morphology, associated risk and molecular disturbances. 11:20-11:40 Standardization for c-erb-b-2 assessment: Immunohistochemestry, CISH, FISH. 11:40-12:00 Cytological assessment of surgical margins in breast pathology and sentinel lymph Fattaneh A. Tavassoli, MD Professor of Pathology and Obstetrics, Gynecology, and Reproductive Sciences; Director, Pathology Women's Health Program, Yale University School of Medicine, EE.UU. Luis Contreras, MD Anátomo Patólogo, Condes. Dr. Álvaro Ibarra Anátomo Patólogo,

7 node. 12:00-12:45 Industry Symposium Roche Innovative solutions to current and future challenges in HER2- negative breast cancer. Condes Edith Perez, MD Professor of Medicine at Mayo Medical School, in Rochester, MN; Director of the Cancer Clinical Study Unit at the Mayo Clinic in Jacksonville, Florida, EE.UU. 12:45-14:00 Lunch Industry Symposium Roche Triple negative disease 14:30-15:00 Plenary Conference: Clinical and pathological issues in basallike breast cancer. 15:00-15:20 Which is the best adjuvant therapy and it sequence for triple negative disease? 15:20-15:40 Triple negative metastasic patient: How do we proceed after antracyclines and taxanes. Dr. José Miguel Reyes, Dr. Luis Cereceda Fattaneh A. Tavassoli, MD Professor of Pathology and Obstetrics, Gynecology, and Reproductive Sciences; Director, Pathology Women's Health Program, Yale University School of Medicine, EE.UU. Edith Perez, MD Professor of Medicine at Mayo Medical School, in Rochester, MN; Director of the Cancer Clinical Study Unit at the Mayo Clinic in Jacksonville, Florida, EE.UU. Dennis J. Slamon, MD, PhD Chief of the Division of Hematology/Oncology To state the difference between triple negative and basal-like tumor. To give the pathological issues that characterized the basal-like breast cancer and correlate these issues with clinical out-come. To discuss the role of adjuvant chemotherapy for this type of patients, the way it must be given and the best schedule for them. To discuss the treatment modalities for these patients, mainly the role of platinum agents or other chemotherapy

8 at UCLA, EE.UU. agents. 15:40-16:00 Coffee Break 16:00-16:30 Molecular therapies for triple negative disease. 16:30-17:00 Plenary Conference: Are we ready for personalized adjuvant breast cancer treatment? Oncotype-DX, Mamma-Print, and others. 17:15-18:45 Industry Symposium Glaxo Optimizing breast cancer treatment erb B2. 18:45 Reception Glaxo Annual Assembly GOCCHI Edith Perez, MD Professor of Medicine at Mayo Medical School, in Rochester, MN; Director of the Cancer Clinical Study Unit at the Mayo Clinic in Jacksonville, Florida, EE.UU. Kent Osborne, MD Director L. Duncan Cancer Center, Baylor Houston, EE.UU. Dennis J. Slamon, MD, PhD Chief of the Division of Hematology/Oncology at UCLA, EE.UU. To discuss the advance of research of new molecules for the treatment of triple negative patients. To make an up-date of the data supporting the use of genetic signaling as predictive and prognostic factor. Friday, April 30, 2010 Time Topic Speaker Aims 09:00-09:30 Plenary Conference: The role of surgery in the metastatic breast cancer: the primary breast tumor and solitary metastases. Dr. Ricardo Schwartz Dr. José Miguel Reyes Monica Morrow, MD Chief of Breast Surgery at Memorial Sloan-Kettering Cancer Center in Manhattan, NY, EE.UU. To discuss the role of surgery in the treatment for patients with metastatic disease and with primary not treated and to discuss the role of surgery for those patients with only one or two, organ confined, lesion(s).

9 09:30-09:50 Is there still a role for adjuvant chemotherapy in postmenopausal patients? 09:50-10:10 Is there still a role for Tamoxifeno in the adjuvant treatment of postmenopausal patients? Dennis J. Slamon, MD, PhD Chief of the Division of Hematology/Oncology at UCLA, EE.UU. Dr. José Miguel Reyes Oncólogo Médico, Condes To discuss the current role of chemotherapy in post menopausal patients, mainly referred to selection and of patients and type of therapy. To discuss the new evidence about the role of TAM and AI in the endocrine treatment of post menopausal breast cancer patients. 10:10-10:30 Coffee Break 10:30-10:50 Role of HER-2 inhibitors in the adjuvant setting. 10:50-11:20 Plenary Conference: Role of HER-2 inhibitors in the metastatic setting. 11:20-11:40 Endocrine adjuvant treatment in the pre-menopausal patient: Role of ovarian ablation/supresion. Edith Perez, MD Professor of Medicine at Mayo Medical School, in Rochester, MN; Director of the Cancer Clinical Study Unit at the Mayo Clinic in Jacksonville, Florida, EE.UU. Dennis J. Slamon, MD, PhD Chief of the Division of Hematology/Oncology at UCLA, EE.UU. Dr. Carlos Regonesi Oncólogo Médico, Condes. To review the achievements in the field of HER-2 inhibition for the adjuvant treatment of breast cancer patients. To highlight the role of HER-2 inhibitors in the management of HER-2 positive disease. To up-date the role of endocrine therapy for premenopausal patients, with special reference to the new data of meta-analysis. 11:40-12:10 Plenary Conference: Dual inhibition: use of growth factor inhibitors and endocrine blockade: Ready for clinical use? 12:10-12:40 Plenary Conference: Minimizing local recurrence: Kent Osborne, MD Director L. Duncan Cancer Center, Baylor Houston, EE.UU. Monica Morrow, MD Chief of Breast To up-date the research and clinical progress of dual o triple association of endocrine therapy and other molecular therapies for the treatment of breast cancer.

10 What is proven and what is not. Surgery at Memorial Sloan-Kettering Cancer Center in Manhattan, NY, EE.UU. Oncoplastic and Breast Reconstruction Surgery 14:30-15:00 Plenary Conference: Breast onco-plastic surgery: Past, present and future. Dr. Hernando Paredes, Dra. Nuvia Aliaga Dr. Eduardo González Cirujano Oncoplástico. Jefe Unidad de Reconstrucción Mamaria, Depto. de Mastología, Instituto Ángel H. Roffo, Buenos Aires, Argentina. 15:00-15:20 Immediate breast reconstruction. Dra. Nuvia Aliaga Cirujana, Centro 15:20-15:40 Breast reconstruction using expanders and prosthesis. 15:40 16:00 Optimizing sequence in radiotherapy and breast reconstruction. 16:00 16:20 Treatment of contralateral breast: with and without implants mastopexy. 16:20-16:40 Technical videos: Skin sparing mastectomy, sentinel lymph node and Dr. Hernando Paredes Cirujano, Centro Dr. Antonio Solá Radioncólogo Médico, Instituto Oncológico, Clínica Las Condes Dr. Alberto Rancati Jefe Servicio Cirugía Plástica y Reconstrucción. Instituto Quirúrgico del Callao, Buenos Aires, Argentina. Dr. Eduardo González Cirujano Oncoplástico. Jefe Unidad de Reconstrucción

11 immediate breast reconstruction with expanders. Skin sparing mastectomy, axillary clearance and immediate reconstruction with microsurgical TRAM. Deferred breast reconstruction with dorsal width and definitive expander. Mamaria, Depto. de Mastología, Instituto Ángel H. Roffo, Buenos Aires, Argentina. 16:40-17:00 Coffee break All 17:00-17:20 Breast reconstruction and lipofiling. Dr. Alberto Rancati Jefe Servicio Cirugía Plástica y Reconstrucción. Instituto Quirúrgico del Callao, Buenos Aires, Argentina. 17:20-17:40 Breast reconstruction with flaps. Dr. Hernando Paredes Cirujano, Centro 17:40-18:00 Breast reduction and conservative management of breast cancer. Dr. Alberto Rancati Jefe Servicio Cirugía Plástica y Reconstrucción. Instituto Quirúrgico del Callao, Buenos Aires, Argentina. 18:00 18:30 Discussion and closing Adjourn